Piramal Critical Care launches Chlorpromazine Hydrochloride injection in US

Piramal Critical Care (PCC), a division of Piramal Pharma Limited, has announced the U.S. launch of Chlorpromazine Hydrochloride for Injection, USP. This medication is available in 25mg/1mL and 50mg/2mL vials, further enhancing PCC’s growing portfolio of generic injectables for critical care.

Chlorpromazine Hydrochloride is widely used in the management of severe nausea, vomiting, and psychotic disorders. With this launch, PCC reinforces its commitment to providing high-quality, affordable solutions to the healthcare industry.

Advertisement

This new product introduction is part of PCC’s ongoing expansion in the generic injectables market. In 2024, PCC made significant strides by launching the first-to-market generic of Edaravone IV Infusion. The company’s portfolio also saw notable additions in 2023, including Pantoprazole Sodium for Injection, USP, and Doxycycline for Injection, USP.

Piramal Critical Care continues to prioritize innovation and accessibility, addressing the needs of healthcare providers and patients alike. By consistently introducing critical medications, PCC strengthens its position as a trusted leader in the generic injectables sector.